Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

91.61 +1.25 (+1.39%)
Streaming Delayed Price Updated: 2:08 PM EDT, May 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
News headline image
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside ↗
Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments. 
Via Benzinga
News headline image
Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike ↗
Moderna, BioNTech and Novavax stocks popped after the CDC noted a recent increase in positive Covid tests. 
Via Investor's Business Daily
News headline image
5 Predictions for the Stock Market in 2025 -- and Which Stocks Will Soar the Most If They're Right ↗
Via The Motley Fool
News headline image
Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy ↗
Pfizer stock is setting up for a wild ride in 2025 as it faces off with an activist and, possibly, Robert F. Kennedy Jr. at HHS. 
Via Investor's Business Daily
News headline image
3 No-Brainer Biotech Stocks to Buy With $200 Right Now ↗
Via The Motley Fool
News headline image
Critical Insights From BioNTech Analyst Ratings: What You Need To Know ↗
 
Via Benzinga
News headline image
The Analyst Landscape: 17 Takes On BioNTech ↗
 
Via Benzinga
News headline image
What Analysts Are Saying About BioNTech Stock ↗
 
Via Benzinga
News headline image
2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid ↗
Via The Motley Fool
News headline image
2 No-Brainer Stocks to Buy Before the End of 2024 ↗
Via The Motley Fool
News headline image
Why Is BioNTech Stock Trading Higher On Friday? ↗
BNT324/DB-1311 trial data show significant antitumor activity in various cancers, with high response rates in small cell lung and prostate cancer patients. 
Via Benzinga
News headline image
5 Top Stocks to Buy in December ↗
Take a closer look at these bargain-bin value stocks, quality dividend stocks, and one scorching-hot growth stock. 
Via The Motley Fool
News headline image
This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth ↗
To gain an edge, this is what you need to know today. 
Via Benzinga
News headline image
Breaking Down BioNTech: 16 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
European And US Vaccine Stocks Are Under Pressure - Here's WHy ↗
Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts. 
Via Benzinga
News headline image
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS ↗
President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services. 
Via Investor's Business Daily
Topics Government
News headline image
BioNTech Stock Got A IBD RS Rating Lift ↗
A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance. 
Via Investor's Business Daily
News headline image
BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition ↗
BioNTech acquires Biotheus for $800 million plus milestone payments, securing global rights to BNT327/PM8002 and expanding its oncology and R&D presence in China. 
Via Benzinga
News headline image
BioNTech to Acquire Biotheus to Boost Oncology Strategy
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential ↗
Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future revenue amid shifting company focus. 
Via Benzinga
News headline image
This Bank of America Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗
 
Via Benzinga
News headline image
Trump's Potential 'Health Czar' Robert F. Kennedy Jr. Rattles Vaccine Stocks: 'Shoot First Reaction' ↗
Donald Trump has said he will give Robert F. Kennedy Jr. a senior role in his incoming administration to advance his "Make America Healthy Again" agenda. 
Via Benzinga
Topics Government
News headline image
BioNTech Se (BNTX) Q3 2024 Earnings Call Transcript ↗
BNTX earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3 ↗
BioNTech's Q3 revenue surged to €1.244 billion, reflecting early COVID-19 vaccine approvals. Net profit rose to €198.1 million, and full-year guidance adjusted downward. 
Via Benzinga
News headline image
BioNTech Jumps On Surprise Profit, Wide Sales Beat; But Lowers Outlook ↗
The company now expects sales to come in at the lower end of its previous guidance. 
Via Investor's Business Daily
News headline image
BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report ↗
Amid the election, and a Fed rate vote, earnings season roars ahead. 
Via Investor's Business Daily
Topics Economy Stocks
News headline image
BioNTech to Host Innovation Series R&D Day on November 14, 2024
From BioNTech SE
Via GlobeNewswire
News headline image
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising? ↗
This drugmaker's lead candidate could become a top-selling cancer therapy. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.